Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare protein disease: experimental drug targets relapsed amyloidosis

NCT ID NCT06292780

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called linvoseltamab in 220 people with AL amyloidosis that has returned or not improved after prior therapy. The drug aims to reduce abnormal proteins that damage organs like the heart and kidneys. The trial first finds the safest dose, then checks how well the drug controls the disease and improves organ function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis plasma cell myeloma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS

Contacts and locations

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, 05505, South Korea

  • Boston Medical Center

    RECRUITING

    Boston, Massachusetts, 02118, United States

  • City of Hope

    RECRUITING

    Duarte, California, 91010, United States

  • Clinica Universidad de Navarra - Pamplona

    RECRUITING

    Pamplona, Navarre, 31008, Spain

  • Colorado Blood Cancer Institute/SCRI

    RECRUITING

    Denver, Colorado, 80218, United States

  • Hospital Universitari Son Espases

    RECRUITING

    Palma, Balearic Islands, 07120, Spain

  • Hospital de Cabuenes

    RECRUITING

    Gijón, Principality of Asturias, 33203, Spain

  • Karmanos Cancer Institute

    RECRUITING

    Detroit, Michigan, 48201, United States

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • National and Kapodistrian University of Athens

    RECRUITING

    Athens, 11528, Greece

  • Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Roswell Park Comprehensive Cancer Center

    RECRUITING

    Buffalo, New York, 14263, United States

  • SCRI Oncology Partners

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Samsung Medical Center

    RECRUITING

    Seoul, 06351, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

  • Seoul St. Mary's Hospital - The Catholic University of Korea

    RECRUITING

    Seoul, 065791, South Korea

  • The Christie NHS Foundation Trust

    WITHDRAWN

    Manchester, M20 4BQ, United Kingdom

  • University College London Hospitals

    RECRUITING

    London, NW1 2PG, United Kingdom

  • University Hospital La Fe

    RECRUITING

    Valencia, 46026, Spain

  • Universität de Barcelona- Institut d' Investigacions Biomediques August Pi i Sunyer (IDIBAPS)

    RECRUITING

    Barcelona, 08036, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.